About sunvax.x1000.ai

This site is a customer-facing tool for SunVax mRNA Therapeutics Inc. — a Beverly, MA company that builds cell-type-specific lipid nanoparticle (LNP) delivery kits under the SV-Delivery™ brand. It is operated as part of the LIGHT HOPE / x1000.ai research ecosystem.

About SunVax

SunVax is founded and led by Yingzhong Li (President), whose peer-reviewed publications span both academic and company affiliations:

• First author, Communications Biology 2025 (Nature group) — "Cascade amplification of therapeutic payloads for cancer immunotherapy" (PMID 40851032), affiliation SunVax mRNA Therapeutics. The paper reports a 525-fold intratumoral IL-12 amplification in a B16F10 melanoma model. A
• First author, Scientific Reports 2019 (Nature group) — "In vitro evolution of enhanced RNA replicons for immunotherapy" (PMID 31061426), affiliation MIT Department of Biological Engineering and Koch Institute for Integrative Cancer Research. Co-authored with Darrell J. Irvine (HHMI / Ragon Institute) and Ron Weiss (MIT BE). A

We cite this publicly because it is publicly available and grade-A sourced. The site framing remains an unsolicited offer; this background is presented as fact, not endorsement.

What this site is

Four working tools built around SunVax's published data: a kit selector, a product catalog, an experiment designer, and a troubleshooter. The goal is to compress the typical 1-to-3 week sales-email cycle into a 5-minute decision for a wet-lab scientist. Every datum cites a source.

What this site is not

• Not a clinical decision tool. None of the content here informs patient care.
• Not an "AI-driven LNP design" platform. SunVax explicitly uses empirical screening + pattern-finding, not machine learning — and we don't market what SunVax disclaims.
• Not the SunVax order portal. To buy a kit, you go to order.sunvaxmrna.com.
• Not a partnership announcement. The site is an unsolicited tool built around public SunVax data; SunVax has the right to request any change or removal at any time.

Methodology — how claims are graded

• A — directly disclosed by SunVax at a peer conference, on their public website, or in a publication.
• B — disclosed informally (e.g., Q&A transcript) and reasonably attributable.
• C — inferred from cross-correlated public data (e.g., cross-species lipid family).
• D — speculative or unverified. Grade D never appears on this public site.

Honest disclosure

Cell-type-specific LNP delivery is a research-grade technology with real gaps: limited human in vivo data, partially-characterized repeat-dosing immune profile, and mostly mouse-cytokine-construct preclinical work. These gaps are called out on the landing page and on the individual kit pages.

Corrections

Anyone reading this site — including SunVax employees — can request a correction by emailing the contact below. Corrections are applied within one business day and the "last verified" footer date is updated.

Contact

• For SunVax kits, orders, partnership: [email protected]
• For corrections / questions about this tooling: see contact

Tooling credits

Built with Next.js + Tailwind, statically rendered, hosted under x1000.ai. The kit matching logic, troubleshooter decision tree, and experiment designer are all open code — anyone with access to the repository can audit the rules. The landing page, product pages, insights, and other content draw from SunVax public material at sunvaxmrna.com and the SunVax conference presentation of 2026-05-03.